Neuraworx Medical Technology Inc. has closed an oversubscribed Seed funding round led by Nexus NeuroTech Ventures, with participation from Foothill Ventures, Verge HealthTech Fund, Wisconsin Alumni Research Foundation (WARF), and other leading neurotech investors.

“NeuraWorx is addressing a foundational and underexplored mechanism in brain health: cerebrovascular and glymphatic dysfunction, which is increasingly implicated in neurodegenerative and neuropsychiatric diseases,” said John Propst, Ph.D., principal at Nexus NeuroTech Ventures. “What differentiated this opportunity for Nexus was the strength of the underlying physiology, the clarity of the mechanistic hypothesis, and a chain of preclinical and emerging clinical evidence supporting translatability. The company’s development strategy is anchored in objective biomarkers and clinically meaningful endpoints, and we are excited to support the team as they advance a rigorous clinical and regulatory program to translate this platform into durable benefit for patients.”

“This funding validates our science and accelerates our mission to transform brain health for everyone,” NeuraWorx Co-Founder/CEO Chris Minar stated. “We are grateful for Nexus NeuroTech’s strategic partnership and the confidence of our entire investor syndicate. With this capital, we are immediately scaling our team to attract talent in neuroscience, clinical development, and regulatory affairs—people who share our vision of bringing the first-in-class Cerebrovascular Pacing System to patients as quickly and safely as possible.”

NeuraWorx is a clinical-stage neurotechnology company pioneering bioelectronic solutions to restore cerebrovascular and glymphatic function. Based in Excelsior, Minn., the company is developing the Cerebrovascular Pacing System, a proprietary platform designed to enhance brain fluid dynamics for the treatment of central nervous system disorders.

Nexus NeuroTech Ventures is an investment firm dedicated to advancing pioneering technologies— including medical devices, software, diagnostics, technology-enabled care services, and research tools—for brain disorders. Spanning seed through crossover, Nexus invests to help improve the lives of people affected by neurodevelopmental, neurodegenerative, and neuropsychiatric conditions.